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syndrome (CM-IRIS) in a setting in China. A total of 154 AIDS
patients with CM were involved, and 17.5% experienced IRIS at a
median of 27 days after initiation of antiretroviral therapy (ART).
Overall, 3 deaths were directly attributed to IRIS. The
occurrences of CM-IRIS were independently associated with the
pre-ART CD4 + count, pre–C-reactive protein level, and the
timing of ART initiation.
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serious but common complication in cryptococcal meningitis
(CM) patients starting antiretroviral therapy (ART) [1]. It is
reported that paradoxical CM-related IRIS (CM-IRIS) may
occur in 10% to 42% of CM patients after ART initiation, and up
to 66% of them will die of this syndrome [2]. To date, the
pathogenesis of CM-IRIS remains unclear, and the reported
incidence and risk factors of CM-IRIS are inconsistent across
different study populations and settings [3]. China is now facing
an increasing CM-IRIS disease burden [4,5]. However, to our
knowledge, there is still a paucity of studies on CM-IRIS from
this country. Therefore, we undertook this retrospective
cohort study to investigate the epidemiological characterisation
of paradoxical CM-IRIS in China.
A total of 154 ART-naive CM patients with age >15 years and
CD4 + count＜350 cells/μL were entered into this study. After
a median of 34 days of antifungal therapy (usually amphotericin B
with 5-ﬂucytosine and ﬂuconazole for 3-week induction therapy,
and then ﬂuconazole 400mg daily for maintenance therapy), they
initiated ART and received routine follow-up at Public Health
Clinical Center of Changsha City, a 180-bed regional centre for
HIV/AIDS treatment in south-central China, from January 2008
to January 2013. Their demographic, clinical and laboratory data
were systematically collected and evaluated so that we could
identify the incidence, describe the clinical features and explore
the predictors of CM-IRIS.
Table 1 summarises the baseline characteristics of the 154
patients included in this cohort analysis. Of these, 68% were
male, 93% were Han ethnicity, and the mean (SD) age was 38
(9.4) years. Patients started ART at a median of 37 days
(interquartile range [IQR] 28 to 48 days) from CM diagnosis.
After a median follow-up of 3.5 months (IQR 3 to 4 months),
17.5% of patients (95% conﬁdence interval [CI] 12% to 24%)
were identiﬁed as CM-IRIS at a median of 27 days (IQR 17 to 71
days) from initiation of ART, according to the case deﬁnition
developed by the International Network for the Study of HIV-
associated IRIS (INSHI) [6].
Among IRIS patients (n = 27), the most common symptom
was headache (n = 25), followed by photophobia (n = 13) and
papilledema (n = 11). Manifestations unrecorded at baseline
were seizures (n = 2) and hemiplegia (n = 1). The ﬁndings of
cerebrospinal ﬂuid (CSF) indicated increased pressure in all
patients (median 315, IQR 289 to 349 mmH2O), increased
white blood cell count in 89% patients (median 87, IQR 56 to
125 × 106/L), and increased protein in 85% patients (median
0.9, IQR 0.7 to 1.2 g/L). Each variable changed signiﬁcantlyClin Microbiol Infect 2015; 21: 379.e11–379.e14
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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TABLE 1. Summary of cohort characteristics before the ART initiation according to the development of CM-IRIS
Variables All patients (n [ 154) Non-IRIS patients (n[ 127) IRIS patients (n [ 27) p Value
Age, mean (SD), years 37.6 (9.4) 37.3 (9.1) 38.9 (11.0) 0.430
Male sex, n (%) 104 (67.5) 84 (66.1) 20 (74.1) 0.424
Han nationality, n (%) 143 (92.7) 117 (92.1) 26 (96.3) 0.690
BMI, median (IQR) 19.0 (18.2–20.4) 19.1 (18.2–20.5) 18.7 (17.6–19.8) 0.085
Route of HIV infection 0.548
Unsafe sex, n (%) 99 (64.3) 83 (65.4) 16 (59.3)
Blood, n (%) 55 (35.7) 44 (34.7) 11 (40.7)
Duration of HIV infection, mean (SD), years 4.2 (1.4) 4.2 (1.4) 4.2 (1.0) 0.945
CD4 + counta, median (IQR), cells/μL 118 (49–197) 135 (63–210) 57 (21–119) 0.002
Viral loada, median (IQR), log10 copies/mL 4.8 (4.2–5.4) 4.8 (4.2–5.4) 5.3 (4.7–5.6) 0.073
CRP level at the time of ART initiation, median (IQR), mg/L 31.5 (13.2–57.9) 23.7 (12.7–47.0) 61.8 (47.0–82.4) 0.000
CSF cryptococcal antigen titer, median (IQR) 1:512 (1:128–1:1024) 1:512 (1:128–1:1024) 1:1024 (1:256–1:1024) 0.221
CSF ﬁndings
Pressure, mmH2O, median (IQR) 217 (205–244) 217 (205–241) 239 (207–257) 0.155
WBC count, 106/L, median (IQR) 29 (10–67) 27 (9–64) 56 (15–99) 0.041
Protein level, g/L, median (IQR) 0.7 (0.4–0.9) 0.7 (0.4–0.9) 0.7 (0.5–0.9) 0.447
Glucose level, mmol/L, median (IQR) 1.9 (1.4–2.8) 2.0 (1.4–2.9) 1.8 (1.2–2.5) 0.318
Regimen of ART 0.977
AZT + 3TC + NVP, n (%) 97 (63.0) 81 (63.8) 16 (59.3)
d4T + 3TC + NVP, n (%) 26 (16.9) 21 (16.5) 5 (18.5)
AZT + 3TC + EFV, n (%) 16 (10.4) 13 (10.2) 3 (11.1)
d4T + 3TC + EFV, n (%) 15 (9.7) 12 (9.5) 3 (11.1)
CM, cryptococcal meningitis; ART, antiretroviral therapy; IRIS, immune reconstitution inﬂammatory syndrome; BMI, body mass index; IQR, interquartile range; CRP, C-reactive
protein; CSF, cerebrospinal ﬂuid; AZT, zidovudine; 3TC, lamivudine; NVP, nevirapine; d4T, stavudine; EFV, efavirdine.
aGenerally, CD4 count and viral load is tested every 3 or 6 months in China. Thus, the values of CD4 count and viral load presented here may not very exactly reﬂect the actual
immune status of patients at the time of ART initiation.
379.e12 Clinical Microbiology and Infection, Volume 21 Number 4, April 2015 CMIcompared with the ﬁrst episodes of CM (Mann-Whitney U test,
p＜0.05). During the treatment, nonsteroidal and steroid drugs
were used in 8 and 11 patients respectively, therapeutic lumbar
puncture was used in 21 patients, and there was no cessation of
ART or antifungal therapy. Overall, 3 of 27 subjects (11%, 95%
CI 2.3% to 25.4%) died without another clear cause of death,
and the remaining 24 patients survived.
From Cox proportional hazard model, including various
variables (demographic features of patients, CD4 cell count,
viral load, CM antigen titre, C-reactive protein [CRP] level,
timing of ART initiation, type of ART regimen, and pre-ART
CSF ﬁndings), we identiﬁed three statistically signiﬁcant pre-
dictors for CM-IRIS: baseline CD4 count 100 vs.＞100 cells/
μL (hazard ratio [HR] 3.5, 95% CI 1.5 to 7.9, p 0.003), CRP＞
32 vs. 32 mg/L at the time of ART initiation (HR 8.8, 95% CIFIG. 1. Kaplan-Meier survival estimates of clinical epidemiological features
pre–C-reactive protein level (b), and the timing of antiretroviral therapy i
ﬂammatory syndrome; CRP, C-reactive protein; ART, antiretroviral therapy.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect2.7 to 28.2, p < 0.001), and start ART 30 vs. ＞30 days after
CM diagnosis (HR 2.3, 95% CI 1.1 to 4.9, p 0.038). According to
the predictors identiﬁed by Cox model, Kaplan-Meier analyses
for the probability of remaining CM-IRIS free over the follow-
up are presented in Fig. 1.
In the current study, 17.5% of CM patients experience IRIS
after ART initiation. Although this proportion is comparable to
previous retrospective studies conducted in the United States
(21%) [7] and Thailand (19%) [8], in view of the chance of
misdiagnosis and shorter follow-up, we speculate this ﬁgure
may be an underestimation for its real burden in China. In
addition, the 11% mortality in this case series is generally lower
than that in Africa, but high than that in Brazil (0%) [9] and
Thailand (0%) [8]. It is unclear which factors lead to such a
dramatic difference, but several studies suggested that mortalityof paradoxical CM-IRIS development according to pre-CD4 count (a),
nitiation (c). CM-IRIS, cryptococcal-related immune reconstitution in-
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 379.e11–379.e14
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appropriately [9–11]. Thus, the variation in reported mortality
may partly reﬂect difference in capacity for early diagnosis and
quality of case management.
Generally, the evolving clinical proﬁle of CM-IRIS observed
in this cohort is similar with that described elsewhere. The
majority of the patients develop IRIS within 2 months after ART
initiation, and the manifestation of IRIS, compared with the ﬁrst
episode of CM, can be more severe, often involving signiﬁcantly
deteriorative CSF ﬁndings. However, unlike previous reports
[12–14], a shorter time interval (median 27 days) between ART
initiation and IRIS development can be seen in our study. Given
that our data suggest that the CRP level in IRIS patients remains
signiﬁcantly high at the time of ART initiation, we suspect un-
controlled subclinical infection might be one of the main causes
for this ﬁnding.
Many predictors of CM-IRIS, including the timing of ART
initiation and pre-ART CD4 count, have been discussed in
previous studies, but the conclusions seem to be less robust
[12,15–17]. Our analysis conﬁrms that a baseline CD4 + count
100 cells/μL and ART initiation 30 days after CM diagnosis
are strongly associated with paradoxical CM-IRIS, even after
adjustment for other risk factors. These two identiﬁed pre-
dictors may further reinforce the previous similar conclusions.
Furthermore, as reported by a Ugandan cohort [2], we also ﬁnd
that CRP >32 mg/L at the time of ART initiation is a signiﬁcant
predictor for the development of paradoxical CM-IRIS. CRP is a
downstream mediator of interleukin-6, and several studies have
suggested that interleukin-6 might play a critical role in some
pathogen-speciﬁc IRIS pathogenesis [2,18,19]. Thus, dynamic
monitoring of CRP level may be a reliable and easily performed
laboratory test to facilitate prevention or early intervention.
In summary, with the global spread of CM and the expanding
access to ART, a better understanding of CM-IRIS is increas-
ingly urgent. Our data indicate that CM-IRIS often develops
early and can be more severe in comparison with the typical
CM episodes. Moreover, CM-IRIS is associated with the base-
line CD4 count, CRP level, and timing of ART initiation. These
ﬁndings may be helpful for the clinicians when making evidence-
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